These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Meyskens FL; Gerner EW Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725 [TBL] [Abstract][Full Text] [Related]
19. Urinary and erythrocyte polyamines during the evaluation of oral alpha-difluoromethylornithine in a phase I chemoprevention clinical trial. Pendyala L; Creaven PJ; Porter CW Cancer Epidemiol Biomarkers Prev; 1993; 2(3):235-41. PubMed ID: 8318876 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss. Wheeler DL; Ness KJ; Oberley TD; Verma AK Cancer Res; 2003 Jun; 63(12):3037-42. PubMed ID: 12810623 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]